Immunic (IMUX) Stock Price, News & Analysis

Company Overview

Immunic, Inc. (NASDAQ: IMUX) is a clinical‐stage biopharmaceutical company focused on developing oral therapies to treat chronic inflammatory and autoimmune diseases. Founded in 2012, the company is engaged in the research and development of small‐molecule compounds designed to modulate immune pathways. Immunic’s scientific approach seeks to offer patients more convenient, targeted treatment options compared with injectable biologics.

The company’s lead program, vidofludimus calcium (IMU-838), is being evaluated in multiple indications including ulcerative colitis, primary sclerosing cholangitis and relapsing forms of multiple sclerosis. Additional pipeline candidates include IMU-935, aimed at addressing immune‐mediated dermatological and systemic diseases such as psoriasis and systemic lupus erythematosus, and IMU-856, which targets gastrointestinal barrier function for conditions like Crohn’s disease.

Headquartered in New York with a research and development site in Martinsried, Germany, Immunic conducts clinical trials across North America and Europe. The company collaborates with academic institutions and contract research organizations to advance its programs through Phase 2 and Phase 3 studies, while engaging with regulatory authorities to align on development paths and potential market approvals.

Immunic is led by a management team with extensive experience in immunology, clinical development and pharmacology. Guided by a board of directors with backgrounds in biotechnology and pharmaceutical commercialization, the company aims to leverage its specialized expertise to bring innovative, orally administered treatments to patients suffering from debilitating inflammatory diseases.

Key Stats

• Today's Range: $0.76 to $0.83
• 50-Day Range: $0.66 to $1.17
• 52-Week Range: $0.56 to $2.11
• Volume: 1.13 million shs
• Average Volume: 973,746 shs
• Market Capitalization: $79.45 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.60
• Consensus Rating: Buy

Immunic Stock Analysis - MarketRank™

Immunic scored higher than 56% of companies evaluated by MarketBeat, and ranked 448th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Immunic has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Immunic has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Immunic are expected to grow in the coming year, from ($0.94) to ($0.84) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Immunic is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Immunic is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Immunic has a P/B Ratio of 4.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.14% of the float of Immunic has been sold short.

Short Interest Ratio / Days to Cover

Immunic has a short interest ratio ("days to cover") of 4.6.

Change versus previous month

Short interest in Immunic has recently increased by 75.06%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Immunic does not currently pay a dividend.

Dividend Growth

Immunic does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.14% of the float of Immunic has been sold short.

Short Interest Ratio / Days to Cover

Immunic has a short interest ratio ("days to cover") of 4.6.

Change versus previous month

Short interest in Immunic has recently increased by 75.06%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 1.66

News Sentiment

Immunic has a news sentiment score of 1.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Immunic this week, compared to 3 articles on an average week.

Search Interest

33 people have searched for IMUX on MarketBeat in the last 30 days. This is an increase of 94% compared to the previous 30 days.

MarketBeat Follows

Only 5 people have added Immunic to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Immunic insiders have bought more of their company's stock than they have sold. Specifically, they have bought $28,150.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 4.60% of the stock of Immunic is held by insiders.

Percentage Held by Institutions

51.82% of the stock of Immunic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IMUX Stock Analysis - Frequently Asked Questions

How have IMUX shares performed this year?

Immunic's stock was trading at $1.00 at the beginning of the year. Since then, IMUX stock has decreased by 17.1% and is now trading at $0.8292.

How were Immunic's earnings last quarter?

Immunic, Inc. (NASDAQ:IMUX) posted its quarterly earnings data on Thursday, May, 15th. The company reported ($0.25) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.25).

How do I buy shares of Immunic?

Shares of IMUX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Immunic own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Immunic investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Alibaba Group (BABA), CrowdStrike (CRWD), Viking Therapeutics (VKTX), BioXcel Therapeutics (BTAI) and Aldeyra Therapeutics (ALDX).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/08/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IMUX
• CIK: 1280776
• Web: www.immunic-therapeutics.com
• Phone: (332) 255-9818
• Fax: 858-673-6843
• Employees: 70
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Immunic: $11.60
• High Price Target: $28.00
• Low Price Target: $5.00
• Potential Upside/Downside: +1,298.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.25
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$100.51 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -326.95%
• Return on Assets: -181.34%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.74
• Quick Ratio: 0.74

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.20 per share
• Price / Book: 4.15

Miscellaneous

• Outstanding Shares: 95,820,000
• Free Float: 91,410,000
• Market Cap: $79.45 million
• Optionable: Optionable
• Beta: 1.49